Vaccines for viral hemorrhagic fevers - Progress and shortcomings

Current Opinion in Virology

Volumn 3, Issue 3, 2013, Pages 343-351

  Falzarano, Darryl ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DNA VACCINE; LIVE VACCINE; VIRUS VACCINE;

ARTICLE; CELLULAR IMMUNITY; DENGUE; DENGUE VIRUS; EBOLA VIRUS; FILOVIRUS; HUMAN; IMMUNOGENICITY; KYASANUR FOREST DISEASE; LASSA VIRUS; MARBURG VIRUS; MASTOMYS; NAIRO VIRUS; NONHUMAN; OMSK HEMORRHAGIC FEVER; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; VESICULAR STOMATITIS VIRUS; VIRUS ATTENUATION; VIRUS HEMORRHAGIC FEVER; VIRUS LIKE AGENT; YELLOW FEVER FLAVIVIRUS;

EID: 84880310429     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.04.007     Document Type: Review

References (75)

1. G. Grard, J.N. Fair, D. Lee, E. Slikas, I. Steffen, J.J. Muyembe, T. Sittler, N. Veeraraghavan, J.G. Ruby, and C. Wang A novel rhabdovirus associated with acute hemorrhagic fever in central Africa Pediatr Panam 8 2012 e1002924
2. X.J. Yu, M.F. Liang, S.Y. Zhang, Y. Liu, J.D. Li, Y.L. Sun, L. Zhang, Q.F. Zhang, V.L. Popov, and C. Li Fever with thrombocytopenia associated with a novel bunyavirus in China N Engl J Med 364 2011 1523 1532
3. T. Briese, J.T. Paweska, L.K. McMullan, S.K. Hutchison, C. Street, G. Palacios, M.L. Khristova, J. Weyer, R. Swanepoel, and M. Egholm Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa Pediatr Panam 5 2009 e1000455
4. E. Fichet-Calvet, and D.J. Rogers Risk maps of Lassa fever in West Africa PLoS Negl Trop Dis 3 2009 e388
5. I.S. Lukashevich Advanced vaccine candidates for Lassa fever Viruses 4 2012 2514 2557
6. T.W. Geisbert, S. Jones, E.A. Fritz, A.C. Shurtleff, J.B. Geisbert, R. Liebscher, A. Grolla, U. Stroher, L. Fernando, and K.M. Daddario Development of a new vaccine for the prevention of Lassa fever PLoS Med 2 2005 e183
7. L.M. Branco, J.N. Grove, F.J. Geske, M.L. Boisen, I.J. Muncy, S.A. Magliato, L.A. Henderson, R.J. Schoepp, K.A. Cashman, and L.E. Hensley Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever Virol J 7 2010 279
8. I.S. Lukashevich, R. Carrion Jr., M.S. Salvato, K. Mansfield, K. Brasky, J. Zapata, C. Cairo, M. Goicochea, G.E. Hoosien, and A. Ticer Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates Vaccine 26 2008 5246 5254
9. J.C. Zapata, B. Poonia, J. Bryant, H. Davis, E. Ateh, L. George, O. Crasta, Y. Zhang, T. Slezak, and C. Jaing An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Running title: Lassa vaccine in SIV-positive macaques Virol J 10 2013 52
10. X. Jiang, T.J. Dalebout, P.J. Bredenbeek, R. Carrion Jr., K. Brasky, J. Patterson, M. Goicochea, J. Bryant, M.S. Salvato, and I.S. Lukashevich Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs Vaccine 29 2011 1248 1257
11. R. Carrion Jr., P. Bredenbeek, X. Jiang, I. Tretyakova, P. Pushko, and I.S. Lukashevich Vaccine platforms to control arenaviral hemorrhagic fevers J Vaccines Vaccin 3 2012 pii: 1000160
12. A. Ambrosio, M. Saavedra, M. Mariani, G. Gamboa, and A. Maiza Argentine hemorrhagic fever vaccines Hum Vaccin 7 2011 694 700
13. C.G. Albarino, B.H. Bird, A.K. Chakrabarti, K.A. Dodd, M. Flint, E. Bergeron, D.M. White, and S.T. Nichol The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain J Virol 85 2011 10404 10408
14. A.V. Seregin, N.E. Yun, A.L. Poussard, B.H. Peng, J.K. Smith, J.N. Smith, M. Salazar, and S. Paessler TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs Vaccine 28 2010 4713 4718
15. C.S. Borio, M.F. Bilen, M.H. Arguelles, S.E. Goni, J.A. Iserte, G. Glikmann, and M.E. Lozano Antigen vehiculization particles based on the Z protein of Junin virus BMC Biotechnol 12 2012 80
16. J. Kortekaas, O. Ergonul, and R.J. Moormann Interventions against West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus: where are we? Vector Borne Zoonotic Dis 10 2010 709 718
17. O. Ergonul Crimean-Congo haemorrhagic fever Lancet Infect Dis 6 2006 203 214
18. M. Mousavi-Jazi, H. Karlberg, A. Papa, I. Christova, and A. Mirazimi Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine Vaccine 30 2012 6225 6229
19. K. Spik, A. Shurtleff, A.K. McElroy, M.C. Guttieri, J.W. Hooper, and C. SchmalJohn Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus Vaccine 24 2006 4657 4666
20. S.M. Ghiasi, A.H. Salmanian, S. Chinikar, and S. Zakeri Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus Clin Vaccine Immunol 18 2011 2031 2037
21. Y.Z. Zhang, Y. Zou, Z.F. Fu, and A. Plyusnin Hantavirus infections in humans and animals, China Emerg Infect Dis 16 2010 1195 1203
22. J. Hardestam, M. Karlsson, K.I. Falk, G. Olsson, J. Klingstrom, and A. Lundkvist Puumala hantavirus excretion kinetics in bank voles (Myodes glareolus) Emerg Infect Dis 14 2008 1209 1215
23. H.W. Cho, and C.R. Howard Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax) Vaccine 17 1999 2569 2575
24. P. Maes, J. Clement, and M. Van Ranst Recent approaches in hantavirus vaccine development Expert Rev Vaccines 8 2009 67 76
25. G.M. Dong, L. Han, Q. An, W.X. Liu, Y. Kong, and L.H. Yang Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells Chin Med J (Engl) 118 2005 766 768
26. H.W. Cho, C.R. Howard, and H.W. Lee Review of an inactivated vaccine against hantaviruses Intervirology 45 2002 328 333
27. C.S. Schmaljohn Vaccines for hantaviruses: progress and issues Expert Rev Vaccines 11 2012 511 513
28. E.F. Boudreau, M. Josleyn, D. Ullman, D. Fisher, L. Dalrymple, K. Sellers-Myers, P. Loudon, J. Rusnak, R. Rivard, and C. Schmaljohn A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome Vaccine 30 2012 1951 1958
29. B.H. Bird, and S.T. Nichol Breaking the chain: Rift Valley fever virus control via livestock vaccination Curr Opin Virol 2 2012 315 323
30. J. Kortekaas, S.M. de Boer, J. Kant, R.P. Vloet, A.F. Antonis, and R.J. Moormann Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector Vaccine 28 2010 4394 4401
31. S.V. Indran, and T. Ikegami Novel approaches to develop Rift Valley fever vaccines Front Cell Infect Microbiol 2 2012 131
32. M. Bouloy, and R. Flick Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines Antiviral Res 84 2009 101 118
33. B.H. Bird, L.H. Maartens, S. Campbell, B.J. Erasmus, B.R. Erickson, K.A. Dodd, C.F. Spiropoulou, D. Cannon, C.P. Drew, and B. Knust Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep J Virol 85 2011 12901 12909
34. R. Gorchakov, E. Volkova, N. Yun, O. Petrakova, N.S. Linde, S. Paessler, E. Frolova, and I. Frolov Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins Virology 366 2007 212 225
35. M.T. Heise, A. Whitmore, J. Thompson, M. Parsons, A.A. Grobbelaar, A. Kemp, J.T. Paweska, K. Madric, L.J. White, and R. Swanepoel An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus Epidemiol Infect 137 2009 1309 1318
36. N. Bhardwaj, M.T. Heise, and T.M. Ross Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus PLoS Negl Trop Dis 4 2010 e725
37. J.F. Papin, P.H. Verardi, L.A. Jones, F. Monge-Navarro, A.C. Brault, M.R. Holbrook, M.N. Worthy, A.N. Freiberg, and T.D. Yilma Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice Proc Natl Acad Sci U S A 108 2011 14926 14931
38. J. Kortekaas, A.F. Antonis, J. Kant, R.P. Vloet, A. Vogel, N. Oreshkova, S.M. de Boer, B.J. Bosch, and R.J. Moormann Efficacy of three candidate Rift Valley fever vaccines in sheep Vaccine 30 2012 3423 3429
39. D.B. Wallace, C.E. Ellis, A. Espach, S.J. Smith, R.R. Greyling, and G.J. Viljoen Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever Vaccine 24 2006 7181 7189
40. R.K. Soi, F.R. Rurangirwa, T.C. McGuire, P.M. Rwambo, J.C. DeMartini, and T.B. Crawford Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine Clin Vaccine Immunol 17 2010 1842 1849
41. R.B. Mandell, R. Koukuntla, L.J. Mogler, A.K. Carzoli, A.N. Freiberg, M.R. Holbrook, B.K. Martin, W.R. Staplin, N.N. Vahanian, and C.J. Link A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge Virology 397 2010 187 198
42. A. Pichlmair, M. Habjan, H. Unger, and F. Weber Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus Vector Borne Zoonotic Dis 10 2010 701 703
43. S.M. de Boer, J. Kortekaas, A.F. Antonis, J. Kant, J.L. van Oploo, P.J. Rottier, R.J. Moormann, and B.J. Bosch Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge Vaccine 28 2010 2330 2339
44. H. Feldmann, and T.W. Geisbert Ebola haemorrhagic fever Lancet 377 2011 849 862
45. M. Mehedi, A. Groseth, H. Feldmann, and H. Ebihara Clinical aspects of Marburg hemorrhagic fever Future Virol 6 2011 1091 1106
46. N.J. Sullivan, A. Sanchez, P.E. Rollin, Z.Y. Yang, and G.J. Nabel Development of a preventive vaccine for Ebola virus infection in primates Nature 408 2000 605 609
47. S.M. Jones, H. Feldmann, U. Stroher, J.B. Geisbert, L. Fernando, A. Grolla, H.D. Klenk, N.J. Sullivan, V.E. Volchkov, and E.A. Fritz Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Nat Med 11 2005 786 790
48. A. Bukreyev, P.E. Rollin, M.K. Tate, L. Yang, S.R. Zaki, W.J. Shieh, B.R. Murphy, P.L. Collins, and A. Sanchez Successful topical respiratory tract immunization of primates against Ebola virus J Virol 81 2007 6379 6388
49. T.W. Geisbert, and H. Feldmann Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections J Infect Dis 204 Suppl. 3 2011 S1075 S1081
50. D. Falzarano, T.W. Geisbert, and H. Feldmann Progress in filovirus vaccine development: evaluating the potential for clinical use Expert Rev Vaccines 10 2011 63 77
51. D.L. Swenson, K.L. Warfield, T. Larsen, D.A. Alves, S.S. Coberley, and S. Bavari Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses Expert Rev Vaccines 7 2008 417 429
52. W.D. Pratt, D. Wang, D.K. Nichols, M. Luo, J. Woraratanadharm, J.M. Dye, D.H. Holman, and J.Y. Dong Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector Clin Vaccine Immunol 17 2010 572 581
53. J.E. Martin, N.J. Sullivan, M.E. Enama, I.J. Gordon, M. Roederer, R.A. Koup, R.T. Bailer, B.K. Chakrabarti, M.A. Bailey, and P.L. Gomez A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial Clin Vaccine Immunol 13 2006 1267 1277
54. N.J. Sullivan, L. Hensley, C. Asiedu, T.W. Geisbert, D. Stanley, J. Johnson, A. Honko, G. Olinger, M. Bailey, and J.B. Geisbert CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates Nat Med 17 2011 1128 1131
55. J.E. Ledgerwood, P. Costner, N. Desai, L. Holman, M.E. Enama, G. Yamshchikov, S. Mulangu, Z. Hu, C.A. Andrews, and R.A. Sheets A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults Vaccine 29 2010 304 313
56. J.S. Richardson, S. Pillet, A.J. Bello, and G.P. Kobinger Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates J Virol 87 2013 3668 3677
57. C.E. Mire, A.D. Miller, A. Carville, S.V. Westmoreland, J.B. Geisbert, K.G. Mansfield, H. Feldmann, L.E. Hensley, and T.W. Geisbert Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates PLoS Negl Trop Dis 6 2012 e1567
58. N.J. Sullivan, J.E. Martin, B.S. Graham, and G.J. Nabel Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule Nat Rev Microbiol 7 2009 393 400
59. A. Marzi, F. Engelmann, F. Feldamnn, K. Haberthur, W.L. Shupert, D. Brining, D.P. Scott, T.W. Geisbert, Y. Kawaoka, and M.G. Katze Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates Proc Natl Acad Sci U S A 110 1893
60. F.X. Heinz, and K. Stiasny Flaviviruses and flavivirus vaccines Vaccine 30 2012 4301 4306
61. J. Schmitz, J. Roehrig, A. Barrett, and J. Hombach Next generation dengue vaccines: a review of candidates in preclinical development Vaccine 29 2011 7276 7284
62. J. Lang Development of Sanofi Pasteur tetravalent dengue vaccine Rev Inst Med Trop Sao Paulo 54 Suppl. 18 2012 S15 S17
63. A. Sabchareon, D. Wallace, C. Sirivichayakul, K. Limkittikul, P. Chanthavanich, S. Suvannadabba, V. Jiwariyavej, W. Dulyachai, K. Pengsaa, and T.A. Wartel Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 2012 1559 1567
64. M.R. Holbrook Kyasanur forest disease Antiviral Res 96 2012 353 362
65. D. Ruzek, V.V. Yakimenko, L.S. Karan, and S.E. Tkachev Omsk haemorrhagic fever Lancet 376 2010 2104 2113
66. K.K. Orlinger, Y. Hofmeister, R. Fritz, G.W. Holzer, F.G. Falkner, B. Unger, A. Loew-Baselli, E.M. Poellabauer, H.J. Ehrlich, and P.N. Barrett A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans J Infect Dis 203 2011 1556 1564
67. L. Terekhina, N. Pripuzova, M. Vorovitch, Y. Rogova, L. Romanova, N. Tereshkina, A. Timofeev, and G. Karganova Inactivated vaccine against tick-borne encephalitis virus as surrogate vaccine against Omsk hemorrhagic fever virus Antiviral Res 90 2011 A45
68. E.M. Pollabauer, B.G. Pavlova, A. Low-Baselli, S. Fritsch, R. Prymula, R. Angermayr, W. Draxler, C. Firth, J. Bosman, and B. Valenta Comparison of immunogenicity and safety between two paediatric TBE vaccines Vaccine 28 2010 4680 4685
69. E.S. Jentes, G. Poumerol, M.D. Gershman, D.R. Hill, J. Lemarchand, R.F. Lewis, J.E. Staples, O. Tomori, A. Wilder-Smith, and T.P. Monath The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever Lancet Infect Dis 11 2011 622 632
70. WHO Yellow Fever 2011 http://www.who.int/mediacentre/factsheets/fs100/en/
71. A.Y. Khromava, R.B. Eidex, L.H. Weld, K.S. Kohl, R.D. Bradshaw, R.T. Chen, and M.S. Cetron Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events Vaccine 23 2005 3256 3263
72. J.G. Julander, D.W. Trent, and T.P. Monath Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model Vaccine 29 2011 6008 6016
73. B. Schafer, G.W. Holzer, A. Joachimsthaler, S. Coulibaly, M. Schwendinger, B.A. Crowe, T.R. Kreil, P.N. Barrett, and F.G. Falkner Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever PLoS ONE 6 2011 e24505
74. T.P. Monath, E. Fowler, C.T. Johnson, J. Balser, M.J. Morin, M. Sisti, and D.W. Trent An inactivated cell-culture vaccine against yellow fever N Engl J Med 364 2011 1326 1333
75. T.P. Monath, C.K. Lee, J.G. Julander, A. Brown, D.W. Beasley, D.M. Watts, E. Hayman, P. Guertin, J. Makowiecki, and J. Crowell Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity Vaccine 28 2010 3827 3840